Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
Abstract Background Previous studies evaluating antiangiogenic agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma (HCC) have shown encouraging results. This study was conducted to investigate the efficacy and safety of donafenib combined with sintilimab (Don-Sin) for...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13605-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823862002095751168 |
|---|---|
| author | Xiaoyang Hong Yongjian Guo Wenbo Shi Kangshun Zhu Licong Liang Liteng Lin Ye Chen Jingwen Zhou Jingjun Huang Jiabai Huang Yaozhu Wu Wensou Huang Mingyue Cai |
| author_facet | Xiaoyang Hong Yongjian Guo Wenbo Shi Kangshun Zhu Licong Liang Liteng Lin Ye Chen Jingwen Zhou Jingjun Huang Jiabai Huang Yaozhu Wu Wensou Huang Mingyue Cai |
| author_sort | Xiaoyang Hong |
| collection | DOAJ |
| description | Abstract Background Previous studies evaluating antiangiogenic agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma (HCC) have shown encouraging results. This study was conducted to investigate the efficacy and safety of donafenib combined with sintilimab (Don-Sin) for advanced HCC. Methods This was a single-center, single-arm phase II trial recruiting patients with BCLC stage C HCC. A safety run-in cohort was planned with the first 6 patients receiving oral donafenib 200 mg twice daily and intravenous sintilimab 200 mg once every 3 weeks. Dose-limiting toxicities (DLTs) were evaluated to determine the recommended dose of donafenib for those enrolled thereafter. The primary endpoint of this study was progression-free survival (PFS) per mRECIST. Results 30 patients were enrolled. As 3 patients (50.0%) experienced DLTs during safety run-in, the initial dose of donafenib was adjusted to 200 mg once daily for subsequent patients. The primary endpoint was met with a median PFS of 6.2 (95% confidence interval [CI], 4.4-8.0) months per mRECIST (6.3 [95% CI, 5.4–7.2] months per RECIST 1.1). The objective response rate was 23.3% per mRECIST and 16.7% per RECIST 1.1, while the disease control rate reached 76.7% per mRECIST/RECIST 1.1. The median overall survival was 16.0 (95% CI, 13.5–18.5) months. Treatment-related adverse events (TRAEs) occurred in 28 patients (93.3%) and grade 3 TRAEs were observed in 9 patients (30.0%). Conclusions Don-Sin showed promising antitumor effects with an acceptable safety profile in patients with advanced stage HCC. The preliminary findings need to be further evaluated in phase III randomized controlled trials. Trial registration ClinicalTrials.gov (identifier: NCT05162352; date of registration: December 4, 2021). |
| format | Article |
| id | doaj-art-cd426b94b0b9468dad8538c532ab3a3b |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-cd426b94b0b9468dad8538c532ab3a3b2025-02-09T12:41:25ZengBMCBMC Cancer1471-24072025-02-0125111010.1186/s12885-025-13605-2Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trialXiaoyang Hong0Yongjian Guo1Wenbo Shi2Kangshun Zhu3Licong Liang4Liteng Lin5Ye Chen6Jingwen Zhou7Jingjun Huang8Jiabai Huang9Yaozhu Wu10Wensou Huang11Mingyue Cai12Department of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityDepartment of Minimally Invasive Interventional Radiology, the Second Affiliated Hospital, Guangzhou Medical UniversityAbstract Background Previous studies evaluating antiangiogenic agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma (HCC) have shown encouraging results. This study was conducted to investigate the efficacy and safety of donafenib combined with sintilimab (Don-Sin) for advanced HCC. Methods This was a single-center, single-arm phase II trial recruiting patients with BCLC stage C HCC. A safety run-in cohort was planned with the first 6 patients receiving oral donafenib 200 mg twice daily and intravenous sintilimab 200 mg once every 3 weeks. Dose-limiting toxicities (DLTs) were evaluated to determine the recommended dose of donafenib for those enrolled thereafter. The primary endpoint of this study was progression-free survival (PFS) per mRECIST. Results 30 patients were enrolled. As 3 patients (50.0%) experienced DLTs during safety run-in, the initial dose of donafenib was adjusted to 200 mg once daily for subsequent patients. The primary endpoint was met with a median PFS of 6.2 (95% confidence interval [CI], 4.4-8.0) months per mRECIST (6.3 [95% CI, 5.4–7.2] months per RECIST 1.1). The objective response rate was 23.3% per mRECIST and 16.7% per RECIST 1.1, while the disease control rate reached 76.7% per mRECIST/RECIST 1.1. The median overall survival was 16.0 (95% CI, 13.5–18.5) months. Treatment-related adverse events (TRAEs) occurred in 28 patients (93.3%) and grade 3 TRAEs were observed in 9 patients (30.0%). Conclusions Don-Sin showed promising antitumor effects with an acceptable safety profile in patients with advanced stage HCC. The preliminary findings need to be further evaluated in phase III randomized controlled trials. Trial registration ClinicalTrials.gov (identifier: NCT05162352; date of registration: December 4, 2021).https://doi.org/10.1186/s12885-025-13605-2Hepatocellular carcinomaTyrosine-kinase inhibitorDonafenibImmune-checkpoint inhibitorProgrammed death 1 inhibitorSintilimab |
| spellingShingle | Xiaoyang Hong Yongjian Guo Wenbo Shi Kangshun Zhu Licong Liang Liteng Lin Ye Chen Jingwen Zhou Jingjun Huang Jiabai Huang Yaozhu Wu Wensou Huang Mingyue Cai Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial BMC Cancer Hepatocellular carcinoma Tyrosine-kinase inhibitor Donafenib Immune-checkpoint inhibitor Programmed death 1 inhibitor Sintilimab |
| title | Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial |
| title_full | Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial |
| title_fullStr | Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial |
| title_full_unstemmed | Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial |
| title_short | Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial |
| title_sort | donafenib combined with sintilimab for advanced hepatocellular carcinoma a single arm phase ii trial |
| topic | Hepatocellular carcinoma Tyrosine-kinase inhibitor Donafenib Immune-checkpoint inhibitor Programmed death 1 inhibitor Sintilimab |
| url | https://doi.org/10.1186/s12885-025-13605-2 |
| work_keys_str_mv | AT xiaoyanghong donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT yongjianguo donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT wenboshi donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT kangshunzhu donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT licongliang donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT litenglin donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT yechen donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT jingwenzhou donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT jingjunhuang donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT jiabaihuang donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT yaozhuwu donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT wensouhuang donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial AT mingyuecai donafenibcombinedwithsintilimabforadvancedhepatocellularcarcinomaasinglearmphaseiitrial |